Sibeprenlimab, Sibeprenlimab placebo
417-201-00042
Phase 2 small_molecule active
Quick answer
Sibeprenlimab, Sibeprenlimab placebo for Treatment of Sjögren’s disease is a Phase 2 program (small_molecule) at Otsuka Novel Products GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Otsuka Novel Products GmbH
- Indication
- Treatment of Sjögren’s disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active